CU Anschutz Receives FDA Clearance for CAR T-Cell Cancer Therapy Trial

The University of Colorado Anschutz has received clearance from the U.S. Food and Drug Administration (FDA) to begin a clinical trial investigating an experimental CAR T-cell therapy for adults with advanced colorectal cancer and pediatric patients with certain solid tumors.

Developed by CU Anschutz researchers, the treatment uses genetically modified immune cells designed to target two pathways associated with tumor growth and immune resistance. The therapy will be manufactured at the Gates Biomanufacturing Facility on the Anschutz Medical Campus, demonstrating the value of bringing research, biotechnology manufacturing and clinical care together within a connected innovation ecosystem.

Read the full announcement: FDA Clears Clinical Trial Using CAR T-Cells to Fight Colorectal Cancer

Source: CU Anschutz